MYC and lymphoma: ART is effective against adult T-cell leukemia/lymphoma by blocking G1 and/or G2/M phases, reducing the expression of cyclin-dependent kinases 1/2/4/6, cyclin B1/D2/E, and c-Myc, and increasing the expression of p21 (Ishikawa et al., 2020).